Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease
Analysts Release Price Targets And Ratings For Gossamer Bio Inc. (GOSS)
02:00pm, Saturday, 26'th Feb 2022 Stocks Register
Gossamer Bio Inc. (NASDAQ:GOSS) concluded the trading at $9.25 on Friday, February 25 with a fall of -4.64% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $9.70 and 5Y monthly beta was reading 0.98 with its price kept floating in the … Analysts Release Price Targets And Ratings For Gossamer Bio Inc. (GOSS) Read More »
Emerald Mutual Fund Advisers Trust Purchases 316,667 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)
06:16pm, Wednesday, 15'th Dec 2021 Dakota Financial News
Emerald Mutual Fund Advisers Trust raised its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 25.1% in the third quarter, Holdings Channel reports. The fund owned 1,577,747 shares of the companys stock after buying an additional 316,667 shares during the quarter. Emerald Mutual Fund Advisers Trusts holdings in Gossamer Bio were worth $19,832,000 as []
Gossamer Bio (NASDAQ:GOSS) Shares Gap Down to $11.04
05:44pm, Monday, 06'th Dec 2021 Dakota Financial News
Gossamer Bio, Inc. (NASDAQ:GOSS) shares gapped down before the market opened on Monday . The stock had previously closed at $11.04, but opened at $10.16. Gossamer Bio shares last traded at $10.26, with a volume of 417 shares changing hands. GOSS has been the subject of a number of research analyst reports. Zacks Investment Research []
Gossamer Bio (NASDAQ:GOSS) Upgraded to Hold by Zacks Investment Research
08:42am, Friday, 26'th Nov 2021 Dakota Financial News
Zacks Investment Research upgraded shares of Gossamer Bio (NASDAQ:GOSS) from a sell rating to a hold rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and []
Onxeo S.A.: Onxeo Continues to Strengthen its Board of Directors
06:03pm, Tuesday, 23'rd Nov 2021 FinanzNachrichten
Bryan Giraudo, COO CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company''s Board as independent member Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call Transcript
08:39pm, Monday, 08'th Nov 2021
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call Transcript
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
08:36am, Monday, 11'th Oct 2021
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in th
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
04:01pm, Thursday, 07'th Oct 2021
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
08:31am, Tuesday, 21'st Sep 2021
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q2 2021 Results - Earnings Call Transcript
10:55pm, Monday, 09'th Aug 2021
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q2 2021 Results - Earnings Call Transcript
Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and Colitis Organisation
07:01am, Wednesday, 07'th Jul 2021
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease
Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer
04:01pm, Monday, 21'st Jun 2021
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
07:50am, Tuesday, 20'th Apr 2021
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in th
Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs
07:55am, Friday, 16'th Apr 2021
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in th
